177 Lu-DOTATATE在快速进展的神经内分泌瘤中提供救援疗法,其性能状况不佳
Piyush Aggarwal1, Ajay Kumar1, Ashwani Sood1
1From the Department of Nuclear Medicine.
Clinical nuclear medicine
|March 18, 2024
概括
受体放射性核素疗法 (PRRT) 有益于神经内分泌瘤患者,即使是那些表现不佳的患者. 这些案例表明,PRRT可以改善以前不符合条件的患者的生活质量和存活率.
科学领域:
- 在瘤学瘤学.
- 核医学是一种核医学.
- 医疗成像医学成像
背景情况:
- 受体放射性核素疗法 (PRRT) 对转移性神经内分泌瘤有效.
- 目前的PRRT选择标准不包括表现不佳的患者 (ECOG ≤2或KPS <60).
- 这种排除限制了获得PRRT好处的机会,例如改善生活质量和生存.
研究的目的:
- 评估PRRT在患有转移性神经内分泌瘤和最初表现不佳的患者中的疗效.
- 突出PRRT在更广泛的患者群体中的潜力.
主要方法:
- 对两名患有转移性神经内分泌瘤和表现不佳的患者的案例研究回顾.
- 受体放射性核素疗法 (PRRT) 的使用.
- 根据临床结果,生活质量和存活率评估治疗反应.
主要成果:
- 这两位患者都对PRRT表现出了良好的反应.
- 在这些患者中,PRRT改善了生活质量和日常功能.
- 这些案例表明,PRRT可以对表现不佳的患者有益.
结论:
- PRRT可能是转移性神经内分泌瘤患者的可行的治疗选择,其表现状况不佳.
- 扩大PRRT资格标准可能会使更多的患者受益.
- 需要进一步的研究来证实PRRT在这个人群中的有效性.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...